ClinicalTrials.gg

Program

lurbinectedin

Also written as “Lurbinectedin”, “lurbinectedin (PM01183)” and “Lurbinectedin (PM01183)”.

Its studies are mostly in Small Cell Lung Carcinoma · Breast Neoplasms · Neoplasms · Sarcoma, Ewing · Leiomyosarcoma, led by 5 companies.

Furthest: phase 3, since Apr 10, 201527 company-led studies, 7 open or runningNext primary completion: Dec 31, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
PharmaMar202 open or runningphase 3since Apr 10, 2015Apr 6, 2009Aug 30, 2029phase 3 · NCT06088290
Jazz Pharmaceuticals32 open or runningphase 2since Nov 8, 2021Nov 8, 2021Jan 28, 2028phase 2 · NCT05734066
Luye Pharma Group21 open or runningphase 3since Jul 3, 2024Nov 5, 2020Dec 31, 2027phase 3 · NCT06496048
Gilead Sciences11 open or runningphase 3since Jan 24, 2025Jan 24, 2025Oct 2029phase 3 · NCT06801834
Hoffmann-La Roche11 open or runningphase 3since Oct 12, 2021Oct 12, 2021none ahead

Also a collaborator on its studies: jazz-pharmaceuticals-ireland-limited.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 11 studies since Apr 6, 2009.

  1. May 6, 20152 phase 2 studiesPharmaMar · NCT02454972, NCT02451007
  2. Sep 24, 2015Phase 3 study in Small Cell Lung CarcinomaPharmaMar · NCT02566993 · 613 enrolled · United States, Argentina, Austria and more
  3. Nov 5, 2015Phase 2 study in GlioblastomaPharmaMar · NCT02611024 · 316 enrolled · United States, France, Germany and more
  4. Nov 5, 2020Luye Pharma Group's first study: phase 1 study in Advanced Solid TumorNew to Luye Pharma GroupLuye Pharma Group · NCT04638491 · 32 enrolled · China
  5. Sep 2, 20213 phase 1 studiesPharmaMar · NCT05072106, NCT05063318, NCT05101265
  6. Oct 12, 2021Hoffmann-La Roche's first study: phase 3 study in Small Cell Lung CarcinomaNew to Hoffmann-La RocheHoffmann-La Roche · NCT05091567 · 660 enrolled · United States, Belgium, Germany and more
  7. Nov 8, 2021Jazz Pharmaceuticals's first study: phase 2 study in Neoplasm MetastasisNew to Jazz PharmaceuticalsJazz Pharmaceuticals · NCT05126433 · 47 enrolled · United States
  8. Nov 29, 2021Phase 3 study in Small Cell Lung CarcinomaPharmaMar · NCT05153239 · 705 enrolled · United States, Australia, Austria and more
  9. Feb 2, 2023Phase 2 study in Sarcoma, EwingJazz Pharmaceuticals · NCT05734066 · 60 planned · United States, Canada
  10. Sep 28, 2023Phase 3 study in LeiomyosarcomaPharmaMar · NCT06088290 · 469 enrolled · United States, Austria, Belgium and more
  11. Jul 3, 2024Phase 3 study in Small Cell Lung CarcinomaLuye Pharma Group · NCT06496048 · 180 planned · China
  12. Jan 24, 2025Gilead Sciences's first study: phase 3 study in Extensive Stage Small Cell Lung Cancer (ES-SCLC)New to Gilead SciencesGilead Sciences · NCT06801834 · 695 planned · United States, Argentina, Australia and more
  13. Mar 5, 2026Phase 2 study in Small Cell Lung CarcinomaJazz Pharmaceuticals · NCT07459634 · 50 planned · United States
  14. Nov 6, 2026Primary completion moved from 2028-01-31 to 2029-08-04Date moved laterphase 2 · +18 months · NCT07459634

Ahead

  1. Dec 31, 2027Primary completion: phase 3 study in Small Cell Lung CarcinomaLuye Pharma Group · NCT06496048
  2. Jan 28, 2028Primary completion: phase 2 study in Sarcoma, EwingJazz Pharmaceuticals · NCT05734066
  3. Aug 4, 2029Primary completion: phase 2 study in Small Cell Lung CarcinomaJazz Pharmaceuticals · NCT07459634
  4. Aug 30, 2029Primary completion: phase 3 study in LeiomyosarcomaPharmaMar · NCT06088290

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 27 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07459634Small Cell Lung Carcinoma · United States2RecruitingJazz PharmaceuticalsAug 4, 202950
NCT06801834Extensive Stage Small Cell Lung Cancer (ES-SCLC) · United States, Argentina, Australia and more3RecruitingGilead SciencesOct 2029695
NCT06496048Small Cell Lung Carcinoma · China3RecruitingLuye Pharma GroupDec 31, 2027180
NCT06088290Leiomyosarcoma · United States, Austria, Belgium and more3Active, not recruitingPharmaMarAug 30, 2029469
NCT05734066Sarcoma, Ewing · United States, Canada2RecruitingJazz PharmaceuticalsJan 28, 202860
NCT05153239Small Cell Lung Carcinoma · United States, Australia, Austria and more3CompletedPharmaMarApr 10, 2026705
NCT05126433Neoplasm Metastasis · United States2TerminatedJazz PharmaceuticalsDec 20, 202347
NCT05091567Small Cell Lung Carcinoma · United States, Belgium, Germany and more3Active, not recruitingHoffmann-La RocheJul 29, 2024660
NCT05101265Advanced Solid Tumor · Spain1RecruitingPharmaMarJun 1, 202524
NCT05072106Advanced Solid Tumor · Spain1CompletedPharmaMarJan 18, 202211
NCT05063318Advanced Solid Tumors · Spain1CompletedPharmaMarApr 21, 202214
NCT04638491Advanced Solid Tumor · China1CompletedLuye Pharma GroupNov 4, 202332
NCT02611024Glioblastoma · United States, France, Germany and more2CompletedPharmaMarJul 1, 2025316
NCT02566993Small Cell Lung Carcinoma · United States, Argentina, Austria and more3CompletedPharmaMarFeb 24, 2020613
NCT02451007Solid Tumors · United States, Spain2CompletedPharmaMarAug 19, 201639
NCT02454972Advanced Solid Tumors · United States, Belgium, France and more2CompletedPharmaMarSep 18, 2020345
NCT02421588Ovarian Neoplasms · United States3CompletedPharmaMarOct 12, 2018442
NCT02210364Breast Neoplasms · Belgium, Spain1CompletedPharmaMarOct 201681
NCT01980667Neoplasms · Switzerland, United Kingdom1CompletedPharmaMarJan 5, 201741
NCT01970553Neoplasms · Spain, United Kingdom1CompletedPharmaMarOct 201347
NCT01970540Neuroendocrine Tumors · Spain, United Kingdom1CompletedPharmaMarAug 9, 2017122
NCT01951157Carcinoma, Non-Small-Cell Lung · United States2CompletedPharmaMarNov 201669
NCT01831089Breast Neoplasms · United States, Spain, Switzerland1CompletedPharmaMarJul 201669
NCT01525589Breast Neoplasms · United States, Spain2CompletedPharmaMarOct 2018111
NCT01405391Major Advanced Solid Tumors Other Than Colorectal · United States1CompletedPharmaMarJan 201642
NCT01314599Leukemia · United States1CompletedPharmaMarJul 201545
NCT00877474ADVANCED SOLID TUMORS · United States, Spain1CompletedPharmaMarJun 201130

How it is read

Names in the registry

  • “Lurbinectedin”, 13 entries
  • “lurbinectedin (PM01183)”, 6 entries
  • “Lurbinectedin (PM01183)”, 3 entries
  • “PM01183”, 3 entries
  • “Lurbinectedin (regions/countries where approved and available)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.